Bahram Valamehr - Fate Therapeutics Chief Development Officer
| FATE Stock | USD 0.91 0.03 3.19% |
Executive
Dr. Bahram Valamehr Ph.D. is Chief Development Officer of the company. He has served as our Chief Development Officer since August 2018 and oversees our early development activities including offtheshelf cell therapy product candidates derived from our induced pluripotent stem cell platform. From January 2010 to August 2018, Dr. Valamehr served in roles of increasing responsibility with the Company, most recently from December 2016 to August 2018 as our Vice President of Cancer Immunotherapy where he led the RD activities associated with the Companys immunooncology franchise. Prior to that, Dr. Valamehr played key scientific roles at Amgen, the Center for Cell Control, and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer since 2018.
| Age | 47 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 12278 Scripps Summit Drive, San Diego, CA, United States, 92131 |
| Phone | 858 875 1800 |
| Web | https://www.fatetherapeutics.com |
Bahram Valamehr Latest Insider Activity
Tracking and analyzing the buying and selling activities of Bahram Valamehr against Fate Therapeutics stock is an integral part of due diligence when investing in Fate Therapeutics. Bahram Valamehr insider activity provides valuable insight into whether Fate Therapeutics is net buyers or sellers over its current business cycle. Note, Fate Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Fate Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Bahram Valamehr over two months ago Acquisition by Bahram Valamehr of 1300000 shares of Fate Therapeutics at 1.25 subject to Rule 16b-3 | ||
Bahram Valamehr over two months ago Disposition of 8705 shares by Bahram Valamehr of Fate Therapeutics at 1.54 subject to Rule 16b-3 | ||
Bahram Valamehr over six months ago Acquisition by Bahram Valamehr of 423 shares of Fate Therapeutics at 1.37 subject to Rule 16b-3 | ||
Bahram Valamehr over six months ago Disposition of 2000 shares by Bahram Valamehr of Fate Therapeutics at 4.84 subject to Rule 16b-3 |
Fate Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2581) % which means that it has lost $0.2581 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5421) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics' management efficiency ratios could be used to measure how well Fate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 22, 2025, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.55. At present, Fate Therapeutics' Debt To Assets are projected to slightly decrease based on the last few years of reporting.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Amy MD | Beam Therapeutics | 60 | |
| James JD | Crispr Therapeutics AG | 53 | |
| Douglas CPA | Century Therapeutics | N/A | |
| Jennifer Jarrett | Arcus Biosciences | 50 | |
| Samarth Kulkarni | Crispr Therapeutics AG | 47 | |
| Yvonne Gehring | Arcus Biosciences | N/A | |
| Pia Eaves | Arcus Biosciences | N/A | |
| Sonja MD | Sana Biotechnology | 50 | |
| Joan MBA | Verve Therapeutics | 56 | |
| Peter Rahmer | Relay Therapeutics | N/A | |
| Snehal Patel | Sana Biotechnology | N/A | |
| Nick MD | Century Therapeutics | N/A | |
| Michael Naso | Century Therapeutics | N/A | |
| Deborah Palestrant | Relay Therapeutics | N/A | |
| Kaitlin Duffy | Verve Therapeutics | N/A | |
| Debra DursoBumpus | Blueprint Medicines Corp | 55 | |
| Michael CPA | Blueprint Medicines Corp | 53 | |
| Daniel Poon | Caribou Biosciences | N/A | |
| John MD | Sana Biotechnology | N/A | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| Linea Aspesi | Editas Medicine | 55 | |
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.26 |
Fate Therapeutics Leadership Team
Elected by the shareholders, the Fate Therapeutics' board of directors comprises two types of representatives: Fate Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fate. The board's role is to monitor Fate Therapeutics' management team and ensure that shareholders' interests are well served. Fate Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fate Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Hickingbottom, Senior Development | ||
| Tunde Babalola, Senior Operations | ||
| Andrew Henry, Senior Operations | ||
| Jessica Francis, Vice Operations | ||
| YuWaye MD, Chief Officer | ||
| Cindy Tahl, General Secretary | ||
| Edward III, Chief Officer | ||
| Victor Hong, Vice Finance | ||
| Bahram Valamehr, Chief Development Officer | ||
| Bahram MBA, President Development | ||
| Scott Wolchko, Founder, CEO and President and Director | ||
| Jim MBA, Senior Development | ||
| MS MBA, Chief Officer | ||
| Cindy JD, Corporate Counsel | ||
| Yu Cai, Head Counsel | ||
| Jerome Bressi, Senior Quality | ||
| Mark DVM, Chief Officer | ||
| Sarah Cooley, Senior Vice President - Clinical Translation |
Fate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fate Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (25.27) % | ||||
| Current Valuation | (89.07 M) | ||||
| Shares Outstanding | 114.6 M | ||||
| Shares Owned By Insiders | 2.26 % | ||||
| Shares Owned By Institutions | 89.80 % | ||||
| Number Of Shares Shorted | 13.06 M | ||||
| Price To Earning | (4.35) X | ||||
| Price To Book | 0.33 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share | Quarterly Revenue Growth 0.11 | Return On Assets | Return On Equity |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.